| __timestamp | Intra-Cellular Therapies, Inc. | Veracyte, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 40786000 |
| Thursday, January 1, 2015 | 18187286 | 47876000 |
| Friday, January 1, 2016 | 24758063 | 52035000 |
| Sunday, January 1, 2017 | 23666957 | 55348000 |
| Monday, January 1, 2018 | 30099855 | 65276000 |
| Tuesday, January 1, 2019 | 64947625 | 82720000 |
| Wednesday, January 1, 2020 | 186363444 | 89118000 |
| Friday, January 1, 2021 | 272611040 | 181193000 |
| Saturday, January 1, 2022 | 358782000 | 174078000 |
| Sunday, January 1, 2023 | 409864000 | 184232000 |
In pursuit of knowledge
In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two pioneering companies: Intra-Cellular Therapies, Inc. and Veracyte, Inc., from 2014 to 2023.
Intra-Cellular Therapies has seen a remarkable increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. This surge reflects the company's aggressive expansion and investment in marketing and administrative capabilities to support its innovative therapies.
Veracyte, Inc. also experienced a significant rise, with expenses more than quadrupling over the same period. This growth underscores Veracyte's commitment to expanding its diagnostic solutions and market reach.
Both companies exemplify the strategic allocation of resources to drive growth in the competitive biotech sector.
Operational Costs Compared: SG&A Analysis of GSK plc and Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Veracyte, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and Arrowhead Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Geron Corporation
Comparing SG&A Expenses: Veracyte, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Breaking Down SG&A Expenses: Veracyte, Inc. vs Viridian Therapeutics, Inc.